Journal of psychoactive drugs最新文献

{"title":"Construction and Standardization of Perceived Shame Scale for Young Adults with Paternal Substance Use Disorder in Pakistan.","authors":"Muhammad Nasar Iqbal, Shirmeen Ijaz, Zohaib Ahmed, Fatima Javed, Mujahid Iqbal","doi":"10.1080/02791072.2025.2484378","DOIUrl":"https://doi.org/10.1080/02791072.2025.2484378","url":null,"abstract":"<p><p>Young adults who struggle with paternal substance use disorder frequently experience elevated levels of shame, which are a result of both internalized feelings of inadequacy and societal stigma. This study aims to develop and validate a perceived shame scale with paternal substance use disorder. This study comprises two phases. Phase I involves the development of the perceived shame of paternal substance use disorder scale, and Phase II aims to validate this scale. This study employed a mixed-method research design and purposive sampling technique was used to collect data from 340 participants for exploratory factor analysis (EFA) and 300 participants for confirmatory factor analysis (CFA). Participants, aged 20-30 years (<i>M = 25.12, SD = 3.05</i>) were recruited. The results finalized twenty-two (22) items with four sub-scales after CFA i.e. psychological problems, interpersonal problems, existential problems, and social problems demonstrating excellent validity and reliability. In conclusion, the results provide a useful tool for future research and clinical interventions aimed at addressing paternal substance use disorder and related emotional difficulties, in addition to furthering our understanding of the internalized and societal causes of shame. The findings of this study have important ramifications for developing empathy, lowering stigma, and advancing efficient support networks for those dealing with this difficult problem.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-9"},"PeriodicalIF":2.1,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143719832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Recreational Cannabis Legalization with Frequency of Using Cannabis for Sleep.","authors":"Zoë Panchal, Joseph T Sakai, Jarrod M Ellingson, Stephanie Zellers, Kenneth P Wright, Matt K McGue, Scott Vrieze, John K Hewitt, Robin P Corley, William Iacono, Christian J Hopfer, J Megan Ross","doi":"10.1080/02791072.2025.2484379","DOIUrl":"https://doi.org/10.1080/02791072.2025.2484379","url":null,"abstract":"<p><p>We examined the association of recreational cannabis legalization (RCL) with frequency of using cannabis, alcohol, and sleep medication for sleep and with co-use of cannabis with other sleep aids. We used linear regression models to examine these associations in a population-based sample of adult twins (<i>n</i> = 3,141). Participants (M_age = 37 (SD = 5)) were primarily White (93%), with 5% Hispanic/Latinx, and female (61%). RCL was associated with using cannabis for sleep more frequently even after controlling for cohort, demographics, sleep quality, anxiety, depression, physical health, season, and pre-legalization cannabis use frequency (β = 0.123, <i>p</i> = .001). RCL was not associated with frequency of using alcohol or sleep medication for sleep, or with co-use of cannabis and other sleep aids. More research is needed to determine whether RCL leads to more frequent use of cannabis for sleep.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-10"},"PeriodicalIF":2.1,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabis and Cocaine, Heroin, or Methamphetamine Use and Factors Associated with Multiple Drug Use and Drug Treatment in a Nationally Representative Sample.","authors":"Ellen T Kurtzman, Christine Ramdin, Lewis S Nelson","doi":"10.1080/02791072.2025.2484389","DOIUrl":"https://doi.org/10.1080/02791072.2025.2484389","url":null,"abstract":"<p><p>Cannabis is often used with other illicit drugs. Drawing from leading theories of polysubstance use, we used data from the 2009-2018 National Health and Nutrition Examination Survey to examine the prevalence of reported lifetime use of cannabis and cocaine, heroin, and/or methamphetamine among non-pregnant respondents ages 18-59 years. After identifying the subpopulation that reported using multiple drugs, we used multivariate logistic regression analysis to identify their demographic characteristics and factors associated with drug treatment participation. Within our analytic sample (<i>N</i> = 16,946), 18.7% reported lifetime cannabis use and cocaine, heroin, or methamphetamine use; 1.4% reported using all four of these drugs in their lifetime. Among individuals who reported using multiple drugs, 21.3% reported drug treatment participation. Compared to respondents who had never been in drug treatment, those who had been had higher odds of being non-Hispanic Black (AOR = 2.0, 95% CI 1.5-2.8), being in fair/poor health (AOR = 1.5, 95% CI 1.1-1.9), and reporting more medical conditions (AOR = 1.2, 95% CI 1.1-1.4). Being female, Mexican American, married, and a non-citizen lowered the odds of drug treatment. Having more than a high-school education and having a household income of more than $100,000 also reduced the odds of drug treatment.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-13"},"PeriodicalIF":2.1,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143719806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceived Importance of Counseling Among Patients Receiving Methadone Treatment.","authors":"Declan T Barry, Mark Beitel, Marina Gaeta Gazzola, Suneel Agerwala, Gul Saeed, Kathryn F Eggert, Teresa Roehrich, Connie Hsaio, Mikah Covelli, Iain D Carmichael, Lynn M Madden, Muhammad Hammouri","doi":"10.1080/02791072.2025.2484374","DOIUrl":"https://doi.org/10.1080/02791072.2025.2484374","url":null,"abstract":"<p><p>We examined the perceived importance of counseling and its correlates among patients receiving methadone treatment (MT). Participants were 345 patients attending MT who completed 7-point Likert-type scales from 1 (\"Strongly Disagree\") to 7 (\"Strongly Agree\") to rate agreement with perceived importance of counseling, opioid use disorder (OUD) illness models, and OUD treatment beliefs. We examined predictors of perceived importance of counseling using hierarchical linear regression; steps 1, 2, and 3 were demographics, OUD illness models, and OUD treatment beliefs, respectively. Most (76%) agreed counseling was important (Mean = 5.6, SD = 1.7). Demographics did not contribute significantly to the regression model, F(4, 340) = 0.88, <i>p</i> > .05). R² was significant for Step 2 (F = 2.89, <i>p</i> < .05) but individual OUD illness model variables did not make a significant contribution (F(3, 337) = 1.76, <i>p</i> > .05). The addition of OUD treatment beliefs on Step 3 (positive overall treatment expectation, importance of daily methadone, life-saving benefit of methadone medication, and importance of mutual aid) explained an additional 51% of the variation in perceived importance of counseling and this change in R² was significant, F(4, 333) = 31.17, <i>p</i> < .001. We conclude that most participants perceived counseling to be important and OUD treatment beliefs independently predicted perceived importance of counseling.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-8"},"PeriodicalIF":2.1,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143719882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of Tobacco Use, Dependence, and Motivation to Quit Among Individuals Seeking Treatment for Alcohol and Cannabis Consumption in Catalonia (Spain).","authors":"Cristina Martinez, Judith Saura, Marta Enriquez, Ariadna Feliu, Xavier Roca, Yolanda Castellano, Carmen Cabezas, Josep Maria Suelves, Silvia Mondon, Pablo Barrio, Magali Andreu, Antonia Raich, Francina Fonseca, Laura Masferrer, Pablo Bautista, Esteve Fernandez","doi":"10.1080/02791072.2025.2479102","DOIUrl":"https://doi.org/10.1080/02791072.2025.2479102","url":null,"abstract":"<p><p>Understanding smoking behaviors in vulnerable groups is essential for effective cessation services. This study characterizes tobacco consumption and identifies factors associated with nicotine dependence and motivation to quit among individuals entering alcohol and cannabis treatment programs. A multi-center cross-sectional study was conducted in ten centers in Barcelona province. Participants' sociodemographics and tobacco use were assessed, including cigarette consumption and nicotine dependence (Fagerström test). Self-efficacy and motivation to quit were measured on a 0-10 Likert scale. A decision-tree analysis identified factors linked to moderate-to-high nicotine dependence (Fagerström ≥ 5) and high cessation motivation (≥7). Most participants (96.1%) use tobacco daily, with 57.0% using manufactured and 42.2% roll-your-own (RYO) cigarettes. Mean cigarette consumption was 15.2/day (SD = 8.7), with nicotine dependence (4.4, SD = 2.3). Cannabis users started smoking tobacco earlier than those who used alcohol. Over the past year, two-thirds attempted quitting and 60% had high cessation motivation. Self-efficacy for quitting was moderate (mean = 5.1; SD = 3.3). RYO use, age over 45, and alcohol use were associated with moderate-to-high nicotine dependence (probabilities = 0.52, 0.62, and 0.71, respectively). Having a non-tobacco social network was linked to a high motivation to quit (probability = 0.72). Participants had moderate nicotine dependence, low self-efficacy, and high motivation to quit tobacco. Dependence was higher among RYO users, ≥45 years/old, and people with alcohol use disorder. High motivation was more frequent among those with a non-tobacco social network. Integrating cessation support into substance treatment, focusing on RYO and young users, and promoting self-efficacy and tobacco-free socialization may enhance cessation success.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-15"},"PeriodicalIF":2.1,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in Online Descriptions and Marketing of Derived Intoxicating Cannabis Products.","authors":"Cassidy R LoParco, Carlton Bone, Ashvita Garg, Carla J Berg, Matthew E Rossheim","doi":"10.1080/02791072.2025.2484376","DOIUrl":"https://doi.org/10.1080/02791072.2025.2484376","url":null,"abstract":"<p><p>Given the rapid expansion of the derived intoxicating cannabis product (DICPs) market and product diversity, this study assessed marketing information provided by online retailers regarding specific DICP compounds. In May 2023, we searched \"buy delta thc\" in Google's incognito, selected the 20 most trafficked online retailers, and assessed product descriptions and related marketing claims across DICP compounds. 18/20 websites provided descriptions for various DICPs. The top five themes were psychoactive/intoxicating profile (100% of the 18 sites), physical effects (94%), mental effects (94%), naturalness (83%), and safety recommendations (83%). All DICPs, except for THCA and HHC-O, were described as psychoactive/intoxicating; potency was often discussed in relation to delta-9 or delta-8 THC. Claims related to physical effects included improvements to general health, pain management, sleep/insomnia aid (mostly for delta-9 THC). Each compound was described on at least 1 website as having relaxing/calming effects; all compounds except for THCP were described as having anti-anxiety effects. Safety recommendations included buying from trusted/reputable sources; 12 websites mentioned compounds \"suitable for new users\" (deltas-8,9,10 THC, HHC, THCP, THCV). Findings highlight potentially misleading information in DICP marketing and the need for stricter regulatory oversight, as well as required health warnings to protect and educate consumers.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143700587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mixed-Methods Study of Use and Attitudes About Psychedelics for Therapeutic Purposes Among Low-Income U.S. Veterans Nationally.","authors":"Jack Tsai, Laura Witte, Taylor Fate","doi":"10.1080/02791072.2025.2483705","DOIUrl":"https://doi.org/10.1080/02791072.2025.2483705","url":null,"abstract":"<p><p>There is great public and clinical interest in the use of psychedelics for therapeutic purposes. However, there has been little national study of psychedelic use in the U.S. veteran population. This study used quantitative and qualitative data from a nationally representative survey of 1,031 low-income U.S. veterans who participated in the National Veteran Homeless and Other Poverty Experiences (NV-HOPE) Study in 2023. In the total sample, lifetime prevalence of psychedelic use for therapeutic purposes was 5.6%, and 23.2% believed psychedelics should be legalized for therapeutics. Veterans who reported more behavioral health issues (e.g. mental and substance use disorders) and had a history of psychosocial problems (e.g. homelessness) were more likely to have used psychedelics for therapeutic reasons and more likely to endorse legalization of psychedelics as therapeutics. Qualitative data revealed mixed attitudes with positive attitudes related to personal experiences and beliefs in the potential benefits of psychedelics, while negative attitudes related to concerns about risks of psychedelics and doubts about their treatment effectiveness. These findings highlight opportunities to use psychedelics as therapeutics among low-income veterans, particularly for those with behavioral and social problems. There is also moderate support in this population toward legalization of psychedelics for therapeutic purposes.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-10"},"PeriodicalIF":2.1,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of the Prescribing of Attention-Deficit Hyperactivity Disorder Medication During Pregnancy: A Systematic Review.","authors":"Danielle J Russell, Ebony Quintrell, Caitlin S Wyrwoll, Erin Kelty","doi":"10.1080/02791072.2025.2478085","DOIUrl":"10.1080/02791072.2025.2478085","url":null,"abstract":"<p><p>Attention deficit hyperactivity disorder (ADHD) diagnosis in women has markedly increased in recent years, resulting in an increase of ADHD medication exposure during pregnancy, which has uncertain health risks. It is therefore critical to understand the extent of the issue. The objective of this novel systematic review was to investigate the prevalence of the prescribing of ADHD medication during pregnancy. A systematic review was conducted following preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. The last search was October 13, 2023, for articles examining the prescribing of ADHD medication in pregnancy. Fifteen studies were included. Participants from the United States (<i>n</i> = 4), the Nordic countries (<i>n</i> = 10), Canada (<i>n</i> = 3), and Australia (<i>n</i> = 1) were included. The prevalence of ADHD-medication dispensing during pregnancy ranged from 0.07 to 6.01 per 1,000 pregnancies. Typically, stimulant medications were more prevalent than nonstimulants. The most prevalent ADHD medication dispensed during pregnancy was methylphenidate followed by amphetamine-type medications. There was high heterogeneity (I² = 99.95%) between the studies, making the study data not appropriate for meta-analysis. The prevalence of the prescribing of ADHD medications in pregnancy ranged substantially, with psychostimulant medications most prescribed. Apart from in the Nordic countries, estimates of prevalence were limited.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Patterns of Cannabis Product Adulteration: An Analysis of WEDINOS Data.","authors":"Simon Erridge, Martin Hall, Mikael H Sodergren","doi":"10.1080/02791072.2025.2478087","DOIUrl":"https://doi.org/10.1080/02791072.2025.2478087","url":null,"abstract":"<p><p>The increasing global consumption of cannabis, particularly within unregulated markets, raises concerns about potential health risks associated with contaminants and adulterants. This study investigates the presence of active compounds and adulterants in illicit cannabis products within the UK. Data was identified from 1,635 samples of cannabis products submitted to the Welsh Emerging Drugs & Identification of Novel Substances (WEDINOS). Of these, 695 (42.51%) did not contain any naturally occurring cannabinoids and in 162 (9.91%) samples no active compound was identified. Over one-third (<i>n</i> = 624; 38.17%) of tested samples contained a psychoactive adulterant. The most common were synthetic cannabinoid receptor agonists (<i>n</i> = 435; 26.61%). These findings highlight the potential dangers of unregulated cannabis consumption and emphasize the need for greater consumer awareness and harm reduction strategies. The study also underscores the urgency for policy reform and stricter enforcement of regulations to mitigate the risks associated with adulterated cannabis within the illicit market.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-7"},"PeriodicalIF":2.1,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychedelic Use and Behavioral Addictions.","authors":"Trey Brasher, David Rosen, Marcello Spinella","doi":"10.1080/02791072.2025.2474244","DOIUrl":"https://doi.org/10.1080/02791072.2025.2474244","url":null,"abstract":"<p><p>Recent clinical trials on classic psychedelics for depression and anxiety have raised questions about their potential to treat other psychiatric conditions. Evidence from pre-clinical and clinical research suggests psychedelics may help with substance use disorders, with ongoing registered trials. Behavioral addictions, sharing features with substance addictions, may also respond to psychedelic treatment. This study examined self-reported symptoms of problem gambling, sexual addiction, compulsive buying, and eating disorders in a community sample (<i>N</i> = 1107), alongside measures of well-being (self-transcendence, personal growth, depression/anxiety, etc.), and use of psychedelics and other psychoactive drugs. Significant positive correlations emerged among well-being measures and among behavioral addiction symptoms, with inverse correlations between well-being and behavioral addictions. Psychedelic users reported greater well-being and lower behavioral addiction symptoms, even after controlling for demographics and other drug use. Principal components analysis showed that behavioral addictions formed a single factor, which was combined into a composite score. Multiple regression analyses revealed that major stimulant, alcohol, and nicotine vaping use predicted higher behavioral addiction scores, while psychedelic use uniquely predicted lower scores. These findings suggest psychedelics may aid in treating behavioral addictions. A controlled pilot study or clinical trial is warranted to explore this therapeutic potential further.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-14"},"PeriodicalIF":2.1,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}